Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley, AH Ko - Biologics: Targets and Therapy, 2008 - Taylor & Francis
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
[PDF][PDF] Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley - Biologics: Targets & Therapy, 2008 - scienceopen.com
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley, AH Ko - Biologics: Targets and Therapy, 2008 - dovepress.com
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
[PDF][PDF] Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley - Biologics: Targets & Therapy, 2008 - Citeseer
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
[HTML][HTML] Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley, AH Ko - Biologics: Targets & Therapy, 2008 - ncbi.nlm.nih.gov
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
[PDF][PDF] Erlotinib in the treatment of advanced pancreatic cancer.
RK Kelley, AH Ko - Biologics: targets & therapy, 2008 - scholar.archive.org
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
Erlotinib in the treatment of advanced pancreatic cancer.
RK Kelley, AH Ko - Biologics: targets & therapy, 2008 - escholarship.org
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
[PDF][PDF] Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley - Biologics: Targets & Therapy, 2008 - academia.edu
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley, AH Ko - Biologics, 2008 - search.proquest.com
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
[PDF][PDF] Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley - Biologics: Targets & Therapy, 2008 - researchgate.net
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …